

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/528,577
				Filing Date	March 21, 2005
				First Named Inventor	Ulrich Speck et al.
				Art Unit	March 21, 2005
				Examiner Name	Laura A. Bouchelle
Sheet	1	of	9	Attorney Docket Number	WEICKM-0044

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4 776 337	10-11-1988	PALMAZ ET AL.	
	A2	4 217 894	08-19-1990	FRANETZKI ET AL.	
	A3	4 997 643	03-05-1991	PARTAIN ET AL.	
	A4	5 306 286	10-22-1991	STACK ET AL.	
	A5	5 102 402	04-07-1992	DROR ET AL.	
	A6	5 789 018	08-04-1992	ENGELSON ET AL.	
	A7	5 157 049	10-20-1992	RUDIGER ET AL.	
	A8	5 176 626	01-05-1993	SOEHENDRA ET AL.	
	A9	5 234 456	08-10-1993	SILVESTRIN, THOMAS A	
	A10	5 629 881	05-13-1997	LEEB ET AL.	
	A11	5 980 972	11-06-1999	DING ET AL.	
	A12	6 013 092	01-11-2000	DEHDASHTIAN ET AL.	
	A13	6 071 285	06-06-2000	LASHINSKI ET AL.	
	A14	2001 0037140	11-01-2001	GAUDOIN ET AL.	
	A15	2002 0098278	07-25-2002	BATES ET AL.	
	A16	2003 007944	01-09-2003	O'HALLORAN ET AL.	
	A17	2004 115228	06-17-2004	COSTA ET AL.	
	A18	7 445 792	09-16-2004	TONER ET AL.	
	A19	2004 0224003	11-11-2004	SCHULTZ ET AL.	
	A20	2005 063926	03-24-2005	BATHINA ET AL.	
	A21	2008 0102033	05-01-2008	SPECK ET AL.	
	A22	2008 0118544	05-22-2008	WANG LIXIAO	
	A23	2008 0175887	07-24-2008	WANG LIXIAO	
	A24	2008 0255508	10-16-2008	WANG LIXIAO	
	A25	2008 0255509	10-16-2008	WANG LIXIAO	
	A26	2008 0255510	10-16-2008	WANG LIXIAO	
	A27	6 682 545	01-27-2004	KESTER ET AL.	
	A28	5 814 301	09-29-1998	KLOPP ET AL.	
	A29	2008 010234	05-01-2008	SPECK ET AL.	
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	JP-06-063145	03-08-1994	KUAAYU KK	T ⁶
	B2	JP-07-328124	12-19-1995	TERUMO CORP.	C57
	B3	DE-20122736	08-09-2007	BAYER SCHERING PHARMA AG	C58
	B4	WO-03/41686	05-22-2003	MEDLOGIC GLOBAL LTD.	A29
	B5	JP-2000507930	06-27-2000		B82
	B6	JP-10509691	09-22-1998		B81
Examiner Signature			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

9

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich Speck et al.
Art Unit	March 21, 2005
Examiner Name	Laura A. Bouchelle

Attorney Docket Number WEICKM-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B7	JP-7500585	01-19-1995			A28
	B8	EP-0357003	03-07-1990	CORVITA CORP.		
	B9	WO-90/13293	11-15-1990	UNIV SYRACUSE		
	B10	WO-90/13332	11-15-1990	CEDARS SINAI MEDICAL CENTER		
	B11	WO-91/12779	09-05-1991	MEDTRONIC, INC		
	B12	WO-91/12779	09-05-1991	MEDTRONIC		
	B13	EP-0470246	02-12-1992	MEDTRONIC, INC.		B12
	B14	WO-92/11896	07-23-1992	BOSTON SCIENTIFIC CORP.		
	B15	WO-92/12717	08-06-1992	BREM ET AL.		
	B16	WO-93/06792	04-05-1993	SCIMED LIFE SYSTEMS, INC.		
	B17	WO-93/09765	05-27-1993	AMSDEN ET AL.		
	B18	WO-93/09762	05-27-1993	LONG ET AL.		
	B19	WO-93/11120	06-10-1993	ZYNAXIS TECH., INC.		
	B20	WO-93/11668	06-24-1993	RUSH PRESBYTERIAN ST. LUKE		
	B21	EP-0578998	01-19-1994	STRECKER ERNST		A4
	B22	JP-06-63145	03-08-1994	BUAAYU KK		C57
	B23	WO-94/07529	04-14-1994	NEORX CORP.		
	B24	EP-0604022	06-29-1994	ADVANCED CARDIOVASCULAR SYSTEMS		
	B25	WO-94/16706	08-04-1994	NEORX CORP.		
	B26	EP-0623354	11-09-1994	MEDTRONIC, INC.		
	B27	WO-94/25020	11-10-1994	PHARMACIA AB		
	B28	WO-94/26291	11-24-1994	NEORX CORP.		
	B29	DE-4334272	04-13-1995	STEMBERGER, AXEL, DR.		A82
	B30	EP-673114	09-20-1995	SIEMENS AG		A10
	B31	EP-0681475	11-15-1995	NEORX CORP.		B25
	B32	JP-7-328124	12-19-1995	TERUMO CORP.		C58

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/528,577
				Filing Date	March 21, 2005
				First Named Inventor	Ulrich Speck et al.
				Art Unit	March 21, 2005
				Examiner Name	Laura A. Bouchelle
Sheet	3	of	9	Attorney Docket Number	WEICKM-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B34	EP-0717041	06-19-1996	SQUIBB BRISTOL MYERS CO.		
	B36	EP-0747069	12-11-1996	COOK, INC.		
	B37	WO-97/01327	01-06-1997	MACROCHEM CORP.		
	B38	DE-69119753	01-23-1997	MEDTRONIC, INC.		A5
	B39	WO-97/31674	09-04-1997	BOSTON SCIENTIFIC CORP.		
	B40	EP-0797988	10-01-1997	ANGIOTECH, INC.		
	B41	WO-97/41916	11-23-1997	EMED CORP.		
	B42	WO-98/43618	10-08-1998	NEORX CORP.		
	B43	WO-99/09729	02-25-1999	MAXON SYSTEM, INC		
	B44	WO-99/08729	02-25-1999	BOSTON SCIENTIFIC CORP.		
	B45	WO-99/30684	06-24-1999	SUPERGEN, INC.		
	B46	WO-99/59556	11-25-1999	NASA		
	B47	WO-00/00238	01-06-2000	QUANUM MEDICAL CORP.		
	B48	WO-00/00023	01-06-2000	HYDROMER, INC.		
	B49	EP-0975340	02-02-2000	NEORX CORP.		B42
	B50	WO-00/47197	08-17-2000	QUANUM MEDICAL CORP.		
	B51	EP-1037605	09-27-2000	SUPERGEN, INC.		B45
	B52	EP-1090637	04-11-2001	ANGIOTECH, INC.		
	B53	WO-01/24866	04-12-2001	PENN ST. RES. FOUNDATION		
	B54	WO-01/054748	08-02-2001	EDWARDS LIFESCIENCE CORP.		
	B55	EP-1159974	12-05-2001	ANGIOTECH PHARMA, INC.		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich Speck et al.
Art Unit	March 21, 2005
Examiner Name	Laura A. Bouchelle

Sheet

4

of

9

Attorney Docket Number

WEICKM-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B56	EP-1250166	10-23-2002	EDWARDS LIFE SCIENCE CORP.		B54
	B57	WO04/006976	01-22-2004	COOK, INC.		
	B58	WO-2004/022124	03-18-2004	ABBOTT LAB.		
	B59	EP-1407786	04-14-2004	SCIMED LIFE SYSTEMS		
	B60	EP-1447098	08-08-2004	BOSTON SCIENTIFIC LTD.		
	B61	EP-1512398	03-09-2005	BOSTON SCIENTIFIC CORP.		
	B62	EP-1521603	04-13-2005	COOK, INC.		B57
	B63	EP-1536850	06-08-2005	ABBOTT LAB		B58
	B64	WO-2005/089855	09-29-2005	ABBOTT LAB.		
	B65	WO-2006/023104	03-02-2006	BOSTON SCIENTIFIC CORP.		
	B66	EP-1666070	06-07-2006	ULRICH ET AL.		A21
	B67	EP-1669091	06-14-2006	BOSTON SCIENTIFIC CORP.		
	B68	EP-1695697	08-30-2006	ANGIOTECH, INC.		
	B69	EP-1695698	08-30-2006	ANGIOTECH, INC.		
	B70	EP-1735042	12-27-2006	ABBOTT LAB		B64
	B71	EP-1781209	05-09-2007	BOSTON SCIENTIFIC LTD., SCIMED, INC.		B65
	B72	WO-08/063576	05-29-2008	LUTONIX, INC.		
	B73	WO-09/051615	04-23-2009	LUTONIX, INC.		
	B74	WO-09/051614	04-23-2009	LUTONIX, INC.		
	B75	WO-09/051616	04-23-2009	LUTONIX, INC.		
	B76	WO-09/051618	04-23-2009	WANG LIXIAO		
	B77	EP-2092941	08-26-2009	LUTONIX, INC.		
	B78	EP-2092942	08-26-2009	LUTONIX, INC.		
	B79	EP-2098230	09-09-2009	BOSTON SCIENTIFIC LTD., SCIMED, INC.		
	B80	CA-2 207 025	06-13-1996	WERNER ET AL.		
	B81	WO-97/33552	09-18-1997	WALLACE TECH, INC.		
	B82	CA-2 218 103	10-17-1996	BEHRINGWER KE AG		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/528,577
				<i>Filing Date</i>	March 21, 2005
				<i>First Named Inventor</i>	Ulrich Speck et al.
				<i>Art Unit</i>	March 21, 2005
				<i>Examiner Name</i>	Laura A. Bouchelle
Sheet	5	of	9	<i>Attorney Docket Number</i>	WEICKM-0044

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Japanese Final Rejection in Co-pending Application No. JP2004-538964 dated March 9, 2010.		
	C2	Opposition to corresponding EP1539266 by Boston Scientific Ltd., March 10, 2010.		
	C3	LIGGINS, RICHARD T. ET AL., "Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers," International Journal of Pharmaceutics, 2001, Vol. 222, pp. 19-33		
	C4	DORDUNOO, S. K. ET AL., "Release of taxol from poly(ϵ -caprolactone) pastes: effect of water-soluble additives," Journal of Controlled Release, 1997, Vol. 44, pp. 87-94		
	C5	WICHERT, B ET AL., "Low Molecular weight PLA: a suitable polymer for pulmonary administered microparticles?" J. Microencapsulation, 1993, Vol. 10, No. 2, pp. 195-207		
	C6	NAIRN, JOHN A., "Polymer Characterization," Materials Science & Engineering 5473, 2003, Ch. 3, pp. 43-55		
	C7	LAMBA, NINA M. K. ET AL., "Structure and Physical Characterization of Polyurethanes," Polyurethanes in Biomedical Applications ,Ch. 4, pp.43-52		
	C8	CREMERS ET AL., "V1742 – Paclitaxel-beschichtete PTCA-Katheter: Gibt es Unterschiede? Einfluss von PACCOCATH und DIOR Ballonkathetern auf die Neointimalproliferation an Schweinekoronarien," Clin. Res. Cardiol., 1997		
	C9	CREMERS, B ET AL., "Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model," Clin. Res. Cardiol., 2009, Vol. 98, pp. 325-330		
	C10	GROSSMANN, S., "Neuartige Zubereitungen Hemmung der Neointimalproliferation in verengten Arterien," Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.), November 2006		
	C11	SOLLOTT, STEVEN J. ET AL., "Taxol Inhibits Neointimal Smooth Muscle Cell accumulation after angioplasty in the rat," The Journal of clinical Investigation, April 1995, Vol. 95, pp. 1869-1876		
	C12	BC, "Lippold in Retardarzneiformen" in E. Nürnberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelberg New York, 5 th edition, 1991, pp. 832-840		
	C13	LANGER, R., "New methods of drug delivery," Science, September 28, 1990, Vol. 249, pp. 1527-1533		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

9

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich Speck et al.
Art Unit	March 21, 2005
Examiner Name	Laura A. Bouchelle

Attorney Docket Number

WEICKM-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C14	KIRK-OTHMER, ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, 3 RD Edition, Vol. 17, 1982, John Wiley & Sons, pp. 281-310	
	C15	VOIGT, R., Lehrbuch der pharmazeutischen Technologie, 5 th edition, VEB Verlag Volk und Gesundheit Berlin, 1984, p. 689	
	C16	TAWASHI, R. "The dissolution rates of crystalline drugs," J. Mond. Pharm. 1968, Vol. 4, No. 11, pp. 371-379	
	C17	U. S. 08/094,536 (Priority of D2)	
	C18	Coomber and Gotlieb, Arteriosclerosis, 1990, Vol. 10, No. 2, pp. 215-222	
	C19	BARTOLI ET AL., J. Microencapsulation, 1990, Vol. 7, No. 2, pp. 191-197	
	C20	KATSUDA ET AL., Clin. Ter. Cardiovasc. IX(4), pp. 245-248	
	C21	GARCIA-MATINEZ ET AL., "Effects of taxol on endothelial cells of the developing semilunar heart valves in the chick embryo," Acta Anat, 1988, Vol. 133, pp. 282-288	
	C22	Package Insert for Taxol	
	C23	MULLER ET AL., JACC, 1990, Vol. 17, No. 6, pp. 126B-131B	
	C24	SLEPIAN, in textbook of interventional cardiology, 1990, Section IV, Chapter 32, pp. 647-670	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

9

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich Speck et al.
Art Unit	March 21, 2005
Examiner Name	Laura A. Bouchelle

Attorney Docket Number

WEICKM-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C25	DICHEK ET AL., "Seeding of Intravascular stents with genetically engineered endothelial cells," Circulation, Vol. 80, No. 5, pp.1347-1353	
	C26	Single e-mail from SIGMA Chemical Company of February 15, 2007 to Dr. Sollot confirming that from 1991 – 1993 the material was listed in their catalog as "Taxol," and that the name was changed in their catalog from "taxol" to "paclitaxel" in 1994	
	C27	UK Court of Appeal Decision	
	C28	HIATT ET AL., "Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail," Catheterization and Cardiovascular Interventions, 2002, Vol. 55, pp. 409-417	
	C29	FORTH, W. ET AL. "Allegemeine und spezielle Pharmakologie und Toxikologie," 7 Auflage. Heidelberg: Spektrum Akademischer Verlag, 1996, Chapter, 1, 2, 3.	
	C30	LIGGINS, R. T. ET AL., J. Pharma. Sci., 1997, Vol. 86, pp. 1458-1463	
	C31	MATTHEW, R. T. ET AL., J. Med. Chem., 1992, Vol. 35, pp. 141-151	
	C32	TARR, B. D. et al., "J. Parent Sci. Technol., 1987, Vol. 41, pp. 31-33	
	C33	SWINDELL, C.S. ET AL., J. Med. Chem, 1991, Vol. 34, pp. 1176-1184	
	C34	SHARMA, U. S. ET AL., J. Pharma. Sci., 1995, Vol. 84, pp. 1223-1230	
	C35	U.S. Patent Application 08/062,451 (Priority of D3)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/528,577
				<i>Filing Date</i>	March 21, 2005
				<i>First Named Inventor</i>	Ulrich Speck et al.
				<i>Art Unit</i>	March 21, 2005
				<i>Examiner Name</i>	Laura A. Bouchelle
Sheet	8	of	9	<i>Attorney Docket Number</i>	
WEICKM-0044					

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C36	FDA ONCOLOGY TOOLS APPROVAL SUMMARY FOR PACLITAXEL		
	C37	FDA ONCOLOGY TOOLS PRODUCT LABEL DETAILS IN CONVENTIONAL ORDER FOR PACLITAXEL		
	C38	Technical Leaflet Cremphor EL		
	C39	BARATH ET AL., JACC, 1989, Vol. 13, No 4, pp. 252A		
	C40	COX ET AL., Coronary Artery Disease, 1992, Vol. 3, pp. 237-248		
	C41	VOISARD ET AL., Coronary Artery Disease, 1993, Vol. 4, pp. 935-942		
	C42	Untersuchungen in vitro and in vivo, Zeitschrift fur kardiologie, Band 89, Heft 5, 2000, pp. 390-397		
	C43	Printout from the website of Bayer HealthCare Pharmaceuticals, indicating that Ultravist has been commercially available since 1985		
	C44	Report demonstrating in the C6-ceramide is a lipophilic substance as defined by the patent in suit		
	C45	MITCHEL ET AL., Circulation, October 1994, Vol. 90, pp. 1979-1988		
	C46	KANDARPA ET AL., J. Vasc. Inter. Radiol., November/ December 1997, Vol. 8, pp. 997-1004		
	C47	KANDARPA ET AL., J. Vasc. Inter. Radiol., May/ June 1998, vol. 9, pp. 487-493		
	C48	BARON ET AL., "Cardiovascular Research, June 2000, Vol. 46, pp. 585-594		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

9

of

9

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich Speck et al.
Art Unit	March 21, 2005
Examiner Name	Laura A. Bouchelle

Attorney Docket Number

WEICKM-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C49	Office Action issued by the European Patent Office on September 15, 2005	
	C50	Claims enclosed with Office Action issued by European Patent Office on September 15, 2005	
	C51	Response filed on January 13, 2006	
	C52	Product Information on the DIOR balloon catheter from Eurocor GmbH	
	C53	Copy of the decision to revoke EP1140273 B1 (=D11EP) of October 23, 2007	
	C54	Clinical Cardiology Divergent Effects on Coronary Artery Disease: Abstract from 70 th Scientific Session: Circulation, Vol. 96, no. 8, October 21, 2007	
	C55	Definition of "partition coefficient" Wikipedia	
	C56	KHAN, I ET AL., Drug Development and Industrial Pharmacy, 2005, Vol. 31, pp. 59-78	
	C57	BUAAYK KK, "Balloon Catheter for Intravascular Dosing," Patent Abstracts of Japan, Publication Date: March 8, 1994, English Abstract of JP06-063145	
	C58	TERUMO CORP, "Medicine dosing catheter," Patent Abstracts of Japan, Publication Date: December 19, 1995, English Abstract of JP07-328124	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.